Log In Sign up
The largest database of trusted experimental protocols

Voriconazole

Manufactured by Santa Cruz Biotechnology
Visit Supplier

Voriconazole is a laboratory product offered by Santa Cruz Biotechnology. It is a triazole antifungal agent that functions as an inhibitor of fungal cytochrome P450-dependent 14α-lanosterol demethylase, an enzyme essential for the synthesis of ergosterol, a major component of the fungal cell membrane.

Automatically generated - may contain errors

Lab products found in correlation

Ketoconazole, by Santa Cruz Biotechnology (2 mentions) Itraconazole, by Santa Cruz Biotechnology (2 mentions) Posaconazole, by Santa Cruz Biotechnology (2 mentions) Fluconazole, by ICN Biomedicals (2 mentions) Ni2 nitrilotriacetate nta agarose, by Qiagen (2 mentions) Isavuconazole, by Merck Group (1 mentions) Letrozole, by Santa Cruz Biotechnology (1 mentions) Clotrimazole, by Santa Cruz Biotechnology (1 mentions) Miconazole, by Santa Cruz Biotechnology (1 mentions) Posaconazole, by Selleck Chemicals (1 mentions) Potato dextrose agar (pda), by Thermo Fisher Scientific (1 mentions) Amphotericin b, by Avantor (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Amphotericin b, by Merck Group (1 mentions) Rpmi 1640 medium, by Merck Group (1 mentions)

4 protocols using voriconazole

1

Synthesis and Characterization of Novel Antifungal Compounds

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Large preparations of VNI, FF-VNI, VFV, and F-VFV were synthesized by the Chemical Synthesis Core Facility (Vanderbilt Institute of Chemical Biology),34 (link) and synthesis of their analogues CF3F-VNI and VFV-Cl has been described previously.9 (link),10 (link) The purity of the compounds was >95%. Voriconazole, ketoconazole, itraconazole, and posaconazole were purchased from Santa Cruz Biotechnology (Dallas, TX); isavuconazole was from Sigma-Aldrich, and fluconazole was from ICN Biomedicals. Hydroxypropyl-β-cyclodextrin (HPCD) was purchased from Cyclodextrin Technology Development (Gainesville, FL). DEAE- and CM-Sepharose resins were from GE Healthcare, and Ni2+-nitrilotriacetate (NTA) agarose was purchased from Qiagen.
Hargrove T.Y., Wawrzak Z., Rachakonda G., Nes W.D., Villalta F., Guengerich F.P, & Lepesheva G.I. (2021). Relaxed Substrate Requirements of Sterol 14α-Demethylase from Naegleria fowleri Are Accompanied by Resistance to Inhibition. Journal of medicinal chemistry, 64(23), 17511-17522.
+ Open protocol
+ Expand
2

Preparation of Voriconazole Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Voriconazole and VNO (Santa Cruz Biotechnology, Inc., Dallas, TX) were dissolved in either phosphate-buffered saline (PBS) or 95% ethanol as 30 mM stock solutions and were used immediately or stored at −20°C until used. All manipulations involving these drugs or their photoproducts were performed under dim yellow light (General Electric F32T8 GO, Fairfield, CT).
Ona-Vu K, & Oh D.H. (2015). Voriconazole N-oxide and its UVB photoproduct sensitize keratinocytes to UVA. The British journal of dermatology, 173(3), 751-759.
+ Open protocol
+ Expand
3

Synthesis and Characterization of Azole Antifungals

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
The azole-based drugs ketoconazole, posaconazole,
voriconazole, ravuconazole, clotrimazole, miconazole, letrozole, and
anastrozole were purchased from Santa Cruz Biotechnology (Dallas,
TX), and fluconazole was from ICN Biomedicals. VNI and VFV were synthesized
by the Chemical Synthesis Core Facility (Vanderbilt Institute of Chemical
Biology).70 (link) The synthesis of their analogue
LFV was described previously.68 (link) The purity
of the compounds was >95%. The pyridine derivatives UDO and UDD
were
from DNDi;46 (link) the tetrazole-based compounds
VT116147 (link) and VT159848 (link) were from Mycovia Pharmaceuticals (Durham, NC). Hydroxypropyl-β-cyclodextrin
(HPCD) was purchased from Cyclodextrin Technology Development (Gainesville,
FL). Q- and CM-Sepharose resins were from GE Healthcare, and Ni2+-nitrilotriacetate (NTA) agarose was from Qiagen. The synthesis
of the CYP51 reaction product (3β,5α)-4,4-dimethyl-cholesta-8,14,24-trien-3-ol
(dihydro-FF-MAS) was reported elsewhere.71 (link) All compounds were >95% pure by high-performance liquid chromatography
(HPLC).
Hargrove T.Y., Lamb D.C., Wawrzak Z., Hull M., Kelly S.L., Guengerich F.P, & Lepesheva G.I. (2024). Identification of Potent and Selective Inhibitors of Acanthamoeba: Structural Insights into Sterol 14α-Demethylase as a Key Drug Target. Journal of Medicinal Chemistry, 67(9), 7443-7457.
+ Open protocol
+ Expand
4

Antifungal Susceptibility of Blastomyces

Check if the same lab product or an alternative is used in the 5 most similar protocols
Clinical isolates of Blastomyces spp collected at the University of Wisconsin Hospital between 2004 and 2017 were tested for antifungal susceptibility retrospectively. They were cultured at 35°C for 10–15 days on potato dextrose agar (Oxoid, Hampshire, England) to induce conidial formation. Conidia were then suspended in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, St. Louis, MO) at 1.0 × 105 conidia/mL and 200 µL was added to 96-well plates containing the antifungals. Five antifungals were tested: itraconazole, voriconazole, and isavuconazole (Santa Cruz Biotechnology, Santa Cruz, CA), posaconazole (Selleck Chemicals, Houston, TX), and amphotericin B (AMRESCO, Solon, OH). Stock solutions were prepared in dimethyl sulfoxide (Sigma-Aldrich) except for amphotericin B, which was in sterile water. Drugs were diluted into RPMI medium via serial doubling dilutions, with concentrations ranging from 0.015 to 8.0 µg/mL except for itraconazole, which had concentrations ranging from 0.13 to 64 µg/mL.
Scolarici M.J., King C., Sterkel A., Smith J., Gauthier G, & Saddler C. (2022). The Role of Isavuconazonium Sulphate for the Treatment of Blastomycosis: A Case Series and Antifungal Susceptibility. Open Forum Infectious Diseases, 9(7), ofac220.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!